Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Cysteine-Independent Inhibition of Alzheimer's Disease-like Paired Helical Filament Assembly by Leuco-Methylthioninium (LMT).

Al-Hilaly YK, Pollack SJ, Rickard JE, Simpson M, Raulin AC, Baddeley T, Schellenberger P, Storey JMD, Harrington CR, Wischik CM, Serpell LC.

J Mol Biol. 2018 Aug 16. pii: S0022-2836(18)30560-6. doi: 10.1016/j.jmb.2018.08.010. [Epub ahead of print]

2.

A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy.

Schwab K, Frahm S, Horsley D, Rickard JE, Melis V, Goatman EA, Magbagbeolu M, Douglas M, Leith MG, Baddeley TC, Storey JMD, Riedel G, Wischik CM, Harrington CR, Theuring F.

Front Mol Neurosci. 2018 Jan 10;10:447. doi: 10.3389/fnmol.2017.00447. eCollection 2017.

3.

Modeling Prion-Like Processing of Tau Protein in Alzheimer's Disease for Pharmaceutical Development.

Wischik CM, Schelter BO, Wischik DJ, Storey JMD, Harrington CR.

J Alzheimers Dis. 2018;62(3):1287-1303. doi: 10.3233/JAD-170727.

4.

Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.

Frahm S, Melis V, Horsley D, Rickard JE, Riedel G, Fadda P, Scherma M, Harrington CR, Wischik CM, Theuring F, Schwab K.

Behav Brain Res. 2018 Feb 26;339:153-168. doi: 10.1016/j.bbr.2017.11.025. Epub 2017 Nov 24.

5.

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.

Wilcock GK, Gauthier S, Frisoni GB, Jia J, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Schelter BO, Wischik DJ, Davis CS, Staff RT, Vuksanovic V, Ahearn T, Bracoud L, Shamsi K, Marek K, Seibyl J, Riedel G, Storey JMD, Harrington CR, Wischik CM.

J Alzheimers Dis. 2018;61(1):435-457. doi: 10.3233/JAD-170560.

6.

Alzheimer's Disease-like Paired Helical Filament Assembly from Truncated Tau Protein Is Independent of Disulfide Crosslinking.

Al-Hilaly YK, Pollack SJ, Vadukul DM, Citossi F, Rickard JE, Simpson M, Storey JMD, Harrington CR, Wischik CM, Serpell LC.

J Mol Biol. 2017 Nov 24;429(23):3650-3665. doi: 10.1016/j.jmb.2017.09.007. Epub 2017 Sep 15.

7.

Assays for the Screening and Characterization of Tau Aggregation Inhibitors.

Rickard JE, Horsley D, Wischik CM, Harrington CR.

Methods Mol Biol. 2017;1523:129-140.

PMID:
27975248
8.

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.

Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JM, Harrington CR, Wischik CM.

Lancet. 2016 Dec 10;388(10062):2873-2884. doi: 10.1016/S0140-6736(16)31275-2. Epub 2016 Nov 16.

10.

Monoaminergic neuropathology in Alzheimer's disease.

Šimić G, Babić Leko M, Wray S, Harrington CR, Delalle I, Jovanov-Milošević N, Bažadona D, Buée L, de Silva R, Di Giovanni G, Wischik CM, Hof PR.

Prog Neurobiol. 2017 Apr;151:101-138. doi: 10.1016/j.pneurobio.2016.04.001. Epub 2016 Apr 12. Review.

11.

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease.

Lai RY, Harrington CR, Wischik CM.

Biomolecules. 2016 Apr 8;6(2). pii: E19. doi: 10.3390/biom6020019.

12.

Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models.

Melis V, Magbagbeolu M, Rickard JE, Horsley D, Davidson K, Harrington KA, Goatman K, Goatman EA, Deiana S, Close SP, Zabke C, Stamer K, Dietze S, Schwab K, Storey JM, Harrington CR, Wischik CM, Theuring F, Riedel G.

Behav Pharmacol. 2015 Jun;26(4):353-68. doi: 10.1097/FBP.0000000000000133.

13.

Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.

Harrington CR, Storey JM, Clunas S, Harrington KA, Horsley D, Ishaq A, Kemp SJ, Larch CP, Marshall C, Nicoll SL, Rickard JE, Simpson M, Sinclair JP, Storey LJ, Wischik CM.

J Biol Chem. 2015 Apr 24;290(17):10862-75. doi: 10.1074/jbc.M114.616029. Epub 2015 Mar 10.

14.

The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease.

Flores-Rodríguez P, Ontiveros-Torres MA, Cárdenas-Aguayo MC, Luna-Arias JP, Meraz-Ríos MA, Viramontes-Pintos A, Harrington CR, Wischik CM, Mena R, Florán-Garduño B, Luna-Muñoz J.

Front Neurosci. 2015 Feb 11;9:33. doi: 10.3389/fnins.2015.00033. eCollection 2015.

15.

Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease.

Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JM, Kook KA, Harrington CR.

J Alzheimers Dis. 2015;44(2):705-20. doi: 10.3233/JAD-142874.

PMID:
25550228
16.

Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer's disease and frontotemporal lobar degeneration.

Melis V, Zabke C, Stamer K, Magbagbeolu M, Schwab K, Marschall P, Veh RW, Bachmann S, Deiana S, Moreau PH, Davidson K, Harrington KA, Rickard JE, Horsley D, Garman R, Mazurkiewicz M, Niewiadomska G, Wischik CM, Harrington CR, Riedel G, Theuring F.

Cell Mol Life Sci. 2015 Jun;72(11):2199-222. doi: 10.1007/s00018-014-1804-z. Epub 2014 Dec 19.

17.

Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease.

Baddeley TC, McCaffrey J, Storey JM, Cheung JK, Melis V, Horsley D, Harrington CR, Wischik CM.

J Pharmacol Exp Ther. 2015 Jan;352(1):110-8. doi: 10.1124/jpet.114.219352. Epub 2014 Oct 15.

18.

Tau-aggregation inhibitor therapy for Alzheimer's disease.

Wischik CM, Harrington CR, Storey JM.

Biochem Pharmacol. 2014 Apr 15;88(4):529-39. doi: 10.1016/j.bcp.2013.12.008. Epub 2013 Dec 19. Review.

19.

Stripline resonator and preamplifier for preclinical magnetic resonance imaging at 4.7 T.

Lavdas I, Seton HC, Harrington CR, Wischik CM.

MAGMA. 2011 Dec;24(6):331-7. doi: 10.1007/s10334-011-0273-8. Epub 2011 Aug 4.

PMID:
21814757
20.

Regional cerebral blood flow and aberrant motor behaviour in Alzheimer's disease.

Reilly TJ, Staff RT, Ahearn TS, Bentham P, Wischik CM, Murray AD.

Behav Brain Res. 2011 Sep 23;222(2):375-9. doi: 10.1016/j.bbr.2011.04.003. Epub 2011 Apr 12.

PMID:
21507335
21.

Lewy body variant of Alzheimer's disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alpha-synuclein in medial temporal lobe.

Mukaetova-Ladinska EB, Xuereb JH, Garcia-Sierra F, Hurt J, Gertz HJ, Hills R, Brayne C, Huppert FA, Paykel ES, McGee MA, Jakes R, Honer WG, Harrington CR, Wischik CM.

ScientificWorldJournal. 2009 Dec 16;9:1463-75. doi: 10.1100/tsw.2009.151.

22.

Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine.

Deiana S, Harrington CR, Wischik CM, Riedel G.

Psychopharmacology (Berl). 2009 Jan;202(1-3):53-65. doi: 10.1007/s00213-008-1394-2. Epub 2008 Nov 14.

PMID:
19005644
23.

Thiazin red as a neuropathological tool for the rapid diagnosis of Alzheimer's disease in tissue imprints.

Luna-Muñoz J, Peralta-Ramirez J, Chávez-Macías L, Harrington CR, Wischik CM, Mena R.

Acta Neuropathol. 2008 Nov;116(5):507-15. doi: 10.1007/s00401-008-0431-x. Epub 2008 Sep 23.

PMID:
18810470
24.

Loss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics.

Mukaetova-Ladinska E, Hurt J, Honer WG, Harrington CR, Wischik CM.

Neurosci Lett. 2002 Jan 14;317(3):161-5.

PMID:
11755264
25.
26.

Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease.

Mukaetova-Ladinska EB, Garcia-Siera F, Hurt J, Gertz HJ, Xuereb JH, Hills R, Brayne C, Huppert FA, Paykel ES, McGee M, Jakes R, Honer WG, Harrington CR, Wischik CM.

Am J Pathol. 2000 Aug;157(2):623-36.

27.

The extent of neurofibrillary pathology in perforant pathway neurons is the key determinant of dementia in the very old.

García-Sierra F, Hauw JJ, Duyckaerts C, Wischik CM, Luna-Muñoz J, Mena R.

Acta Neuropathol. 2000 Jul;100(1):29-35.

PMID:
10912917
28.

Alpha-synuclein inclusions in Alzheimer and Lewy body diseases.

Mukaetova-Ladinska EB, Hurt J, Jakes R, Xuereb J, Honer WG, Wischik CM.

J Neuropathol Exp Neurol. 2000 May;59(5):408-17.

PMID:
10888371
29.

Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer's disease.

Gertz HJ, Xuereb J, Huppert F, Brayne C, McGee MA, Paykel E, Harrington C, Mukaetova-Ladinska E, Arendt T, Wischik CM.

Acta Neuropathol. 1998 Feb;95(2):154-8.

PMID:
9498050
30.

Presence of the apolipoprotein E type epsilon 4 allele is not associated with neurofibrillary pathology or biochemical changes to tau protein.

Mukaetova-Ladinska EB, Harrington CR, Roth M, Wischik CM.

Dement Geriatr Cogn Disord. 1997 Sep-Oct;8(5):288-95.

PMID:
9298630
31.

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR.

Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11213-8.

32.

Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population.

Brayne C, Harrington CR, Wischik CM, Huppert FA, Chi LY, Xuereb JH, O'Connor DW, Paykel ES.

Dementia. 1996 May-Jun;7(3):169-74. Review.

PMID:
8740632
33.

Alterations in tau protein metabolism during normal aging.

Mukaetova-Ladinska EB, Harrington CR, Roth M, Wischik CM.

Dementia. 1996 Mar-Apr;7(2):95-103.

PMID:
8866683
34.

Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease.

Mena R, Edwards PC, Harrington CR, Mukaetova-Ladinska EB, Wischik CM.

Acta Neuropathol. 1996;91(6):633-41.

PMID:
8781663
35.

The relationship between clinical dementia and neuropathological staging (Braak) in a very elderly community sample.

Gertz HJ, Xuereb JH, Huppert FA, Brayne C, Krüger H, McGee MA, Paykel ES, Harrington CR, Mukaetova-Ladinska EB, O'Connor DW, Wischik CM.

Eur Arch Psychiatry Clin Neurosci. 1996;246(3):132-6.

PMID:
8739398
36.

Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia.

Harrington CR, Roth M, Xuereb JH, McKenna PJ, Wischik CM.

Neurosci Lett. 1995 Dec 29;202(1-2):101-4.

PMID:
8787841
37.

Changes in a CSF antigen associated with dementia.

Carretero MT, Harrington CR, Wischik CM.

Dementia. 1995 Sep-Oct;6(5):281-5.

PMID:
8528375
38.

Absence of abnormal hyperphosphorylation of tau in intracellular tangles in Alzheimer's disease.

Bondareff W, Harrington CR, Wischik CM, Hauser DL, Roth M.

J Neuropathol Exp Neurol. 1995 Sep;54(5):657-63.

PMID:
7666054
39.

Quantitative analysis of tau protein in paired helical filament preparations: implications for the role of tau protein phosphorylation in PHF assembly in Alzheimer's disease.

Wischik CM, Edwards PC, Lai RY, Gertz HN, Xuereb JH, Paykel ES, Brayne C, Huppert FA, Mukaetova-Ladinska EB, Mena R, et al.

Neurobiol Aging. 1995 May-Jun;16(3):409-17; discussion 418-31.

PMID:
7566350
40.

Monitoring pathological assembly of tau and beta-amyloid proteins in Alzheimer's disease.

Mena R, Edwards P, Pérez-Olvera O, Wischik CM.

Acta Neuropathol. 1995;89(1):50-6.

PMID:
7709731
41.

Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease.

Harrington CR, Louwagie J, Rossau R, Vanmechelen E, Perry RH, Perry EK, Xuereb JH, Roth M, Wischik CM.

Am J Pathol. 1994 Dec;145(6):1472-84.

42.

Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein.

Harrington CR, Perry RH, Perry EK, Hurt J, McKeith IG, Roth M, Wischik CM.

Dementia. 1994 Sep-Oct;5(5):215-28.

PMID:
7951676
43.

Presence of axonal paired helical filament-tau in Alzheimer's disease: submicroscopic localization.

Bondareff W, Harrington CR, McDaniel SW, Wischik CM, Roth M.

J Neurosci Res. 1994 Aug 15;38(6):664-9.

PMID:
7807582
44.

Alzheimer's-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients.

Harrington CR, Wischik CM, McArthur FK, Taylor GA, Edwardson JA, Candy JM.

Lancet. 1994 Apr 23;343(8904):993-7.

PMID:
7909090
45.

Immunohistochemical staging of neurofibrillary degeneration in Alzheimer's disease.

Bondareff W, Harrington C, Wischik CM, Hauser DL, Roth M.

J Neuropathol Exp Neurol. 1994 Mar;53(2):158-64.

PMID:
7509849
47.

Biochemical and anatomical redistribution of tau protein in Alzheimer's disease.

Mukaetova-Ladinska EB, Harrington CR, Roth M, Wischik CM.

Am J Pathol. 1993 Aug;143(2):565-78.

48.

Evidence of subtypes of Alzheimer's disease and implications for etiology.

Bondareff W, Mountjoy CQ, Wischik CM, Hauser DL, LaBree LD, Roth M.

Arch Gen Psychiatry. 1993 May;50(5):350-6.

PMID:
8489324
50.

Differentiation of neuroblastoma cells correlates with an altered splicing pattern of tau RNA.

Montejo de Garcini E, Corrochano L, Wischik CM, Diaz Nido J, Correas I, Avila J.

FEBS Lett. 1992 Mar 24;299(1):10-4.

Supplemental Content

Loading ...
Support Center